Carbetocin was approved by the FDA in 1997 and its heat-stable formulation added to the core list of the EML in 2019 for the prevention of postpartum haemorrhage based on similar effects compared to oxytocin for efficacy and safety outcomes. Contrary to oxytocin, heat-stable carbetocin does not require cold chain transport or refrigerated storage thus offering advantages and reducing the risk of quality loss compared to oxytocin in LMICs. Heat-stable carbetocin is promising for low resource settings.